oxa102 Antibody

What exactly is referred to by "oxa102 antibody" in scientific literature?

Based on current scientific literature, there is no specific antibody documented as "oxa102 antibody." The term "OXA" primarily refers to Class D β-lactamase enzymes in Gram-negative bacteria that hydrolyze carbapenem antibiotics. While several OXA-23-like antibodies have been developed for diagnostic purposes, "oxa102" specifically is not documented in current literature. Researchers should be aware that they may be referring to either:

• An antibody targeting a specific OXA-type β-lactamase variant

• The OXA1L antibody, which targets the mitochondrial protein oxidase (cytochrome c) assembly 1-like protein

When designing experiments or ordering reagents, researchers should clarify which specific OXA target they are investigating to avoid confusion.

How do OXA-class antibodies differ from other antibacterial resistance detection tools?

OXA-class antibodies provide rapid detection of carbapenem-resistant bacteria through immunoassay methods, distinguishing them from molecular and phenotypic methods. Particularly for OXA-23-like antibodies, the immunochromatographic lateral flow tests demonstrate 100% specificity for the OXA-23 subfamily with results available in approximately 20 minutes from culture plate to result. This represents a significant time advantage compared to traditional methods:

The methodological advantage of antibody-based detection is particularly valuable in clinical settings where rapid identification of resistance mechanisms can guide appropriate antimicrobial therapy decisions.

What are the optimal experimental conditions for using OXA1L antibodies in Western blot applications?

For OXA1L antibody (21055-1-AP) Western blot applications, the following protocol has been validated across multiple cell types and tissue samples:

• Sample preparation: HepG2, HeLa, NIH/3T3, L02 cells, mouse liver tissue, or rat liver tissue provide reliable positive controls

• Dilution ratio: 1:2000-1:10000, with optimization recommended for specific experimental systems

• Expected molecular weight: 42 kDa (observed) vs. 49 kDa (calculated)

• Buffer conditions: PBS with 0.02% sodium azide and 50% glycerol pH 7.3 for storage

Researchers should note that the observed molecular weight (42 kDa) differs from the calculated weight (49 kDa), which may indicate post-translational modifications or alternative splicing of the target protein. This discrepancy should be considered when interpreting bands of unexpected molecular weights.

How can researchers successfully apply OXA1L antibodies in immunofluorescence studies?

For optimal immunofluorescence/immunocytochemistry results with OXA1L antibodies:

• Recommended dilution range: 1:400-1:1600

• Validated positive control: HepG2 cells have demonstrated consistent positive signals

• Antigen retrieval: For fixed tissue samples, use TE buffer pH 9.0 or alternatively citrate buffer pH 6.0

• Signal validation: Confirm specificity through knockdown/knockout controls, as supported by published literature using this antibody

The subcellular localization pattern should be consistent with mitochondrial distribution, as OXA1L is involved in the assembly of cytochrome c oxidase and is required for the proper insertion of integral membrane proteins into the mitochondrial inner membrane.

How can researchers address cross-reactivity concerns with antibodies targeting OXA-family proteins?

Cross-reactivity is a significant concern in antibody-based detection of OXA-family proteins due to structural similarities within the family. Researchers should implement the following validation approach:

• Evaluate antibody specificity using knockout/knockdown models where available (supported by publications with the OXA1L antibody)

• Include appropriate negative controls such as:

  • Isotype control antibodies

  • Samples known to be negative for the target

  • Competitive inhibition with purified antigen

• For bacterial OXA detection, consider the following cross-reactivity profile:

  • Sandwich ELISA and ICT formats often show divergent optimal antibody pairings

  • Validate results with secondary detection methods such as PCR or phenotypic testing

Researchers working with OXA-family proteins should consult comprehensive antibody databases such as Observed Antibody Space (containing 1.5B sequences) or PLAbDab (with 150,000+ literature-annotated antibody sequences) to select antibodies with well-documented specificity profiles.

What strategies should be employed when conflicting results emerge using different detection methods for OXA proteins?

When faced with conflicting results across different detection methods, researchers should implement a systematic troubleshooting approach:

• Evaluate methodological differences:

  • For Western blot discrepancies, examine lysis buffer composition, reducing conditions, and gel percentage

  • For immunohistochemistry/immunofluorescence, compare fixation methods, antigen retrieval protocols, and blocking agents

• Consider target protein characteristics:

  • OXA1L has an observed molecular weight (42 kDa) that differs from its calculated weight (49 kDa)

  • Post-translational modifications may affect epitope accessibility

• Implement orthogonal validation methods:

  • Complement antibody-based detection with mass spectrometry

  • Validate protein expression with mRNA quantification

  • Use multiple antibodies targeting different epitopes of the same protein

• For bacterial OXA enzymes, confirm with:

  • Phenotypic antimicrobial susceptibility testing

  • Molecular methods targeting the specific gene

How do antibody-based approaches for detecting OXA-mediated resistance compare with molecular methods in complex clinical samples?

Antibody-based approaches for detecting OXA-mediated resistance offer distinct advantages and limitations compared to molecular methods when analyzing complex clinical samples:

What role do anti-OXA antibodies play in understanding the evolution of antimicrobial resistance?

Anti-OXA antibodies provide valuable tools for tracking the epidemiology and evolution of antimicrobial resistance, particularly in investigating immune evasion mechanisms:

• Serotype prevalence studies: Similar to investigations of Klebsiella pneumoniae LPS O2 serotype prevalence in multidrug-resistant isolates, antibody-based typing can reveal evolutionary trends in bacterial populations under antibiotic pressure

• Immune evasion mechanisms: The finding that immune stealth advantages drive serotype prevalence in resistant bacterial populations (as seen with K. pneumoniae O2 serotype) suggests similar mechanisms may apply to OXA-producing strains

• Therapeutic potential: Just as human monoclonal antibodies against O-antigens showed synergistic protection with meropenem against drug-resistant K. pneumoniae strains, anti-OXA antibodies might have potential as adjunctive therapeutic agents

• Resistance surveillance: By developing standardized panels of anti-OXA antibodies, researchers can monitor the emergence and spread of specific OXA variants across different geographic regions and healthcare settings

How might antibodies against OXA enzymes be incorporated into novel diagnostic platforms?

Emerging diagnostic platforms incorporating anti-OXA antibodies show promise for rapid resistance detection:

• Multiplexed lateral flow assays: Integration of multiple antibodies against different OXA variants and other resistance determinants on a single test device

• Biosensor applications: Coupling anti-OXA antibodies with electrochemical, optical, or piezoelectric transducers for quantitative detection

• Microfluidic systems: Incorporating antibody-based capture with downstream molecular confirmation

• Point-of-care applications: Development of simplified test formats suitable for use in resource-limited settings

Current immunochromatographic lateral flow tests using anti-OXA-23 antibodies already demonstrate rapid turnaround times (20 minutes) with 100% specificity for the target subfamily. Future platforms will likely extend this approach to comprehensive resistance profiling.

How does the binding kinetics of anti-OXA1L antibodies influence their performance in different experimental applications?

The binding kinetics of anti-OXA1L antibodies significantly impact their utility across different experimental applications:

• For Western blot applications:

  • Higher affinity antibodies (lower KD values) permit greater dilution (1:2000-1:10000 recommended for OXA1L antibody 21055-1-AP)

  • Dissociation rates affect signal stability during washing steps

• For immunohistochemistry applications:

  • Antibody penetration into fixed tissues is influenced by molecular size and binding kinetics

  • Recommended dilutions (1:50-1:500 for OXA1L antibody) reflect this balance

• For immunoprecipitation applications:

  • Association rates determine capture efficiency

  • Stability of antibody-antigen complex during washing affects specificity

• Comparative example from other fields:

  • Anti-Tissue Factor antibody mAb (clone 25A3) binds with high affinity (KD = 0.86 nmol/L), enabling efficient targeting in therapeutic applications

  • Similar high-affinity binding characteristics would benefit anti-OXA antibodies in diagnostic applications

Researchers should consider these kinetic parameters when selecting antibodies for specific applications, particularly when trying to detect low-abundance targets or when working with complex sample matrices.